Skip to main content

Having technical issues with zoom?  Call into the booth and use the meeting ID: 8581 444 8969

        +1 669 900 9128 US (San Jose)
        +1 346 248 7799 US (Houston)
        +1 253 215 8782 US (Tacoma)
        +1 312 626 6799 US (Chicago)
        +1 646 558 8656 US (New York)
        +1 301 715 8592 US (Washington DC)

Find your local number: https://us02web.zoom.us/u/kcgMX6H3vN


Hemophilia, a rare hematological disease, has been a key focus for Pfizer, and significant progress has been made. A century ago, children with hemophilia, a blood-clotting disorder that causes abnormal bleeding, rarely survived past the age of eight. Today, it is a treatable rare disease, and patients who receive treatment can expect to live relatively normal and active lives. At Pfizer, developing therapies for this disease has been a priority for over 18 years. While there is still no cure, we are moving closer to one with pioneering approaches.

https://www.pfizer.com/health-wellness/disease-conditions/rare-diseases/hemophilia

Powered by Firespring